Bisigniano L, López-Rivera A, Tagliafichi V, Fernández V, Soratti C
Scientific-Technical Office at INCUCAI (National Institute of Procurement and Transplantation in Argentina-Ministry of Health), Buenos Aires, Argentina.
Transplant Proc. 2012 Sep;44(7):2242-5. doi: 10.1016/j.transproceed.2012.07.117.
With improvements in short-term kidney graft and patient survival, focus has shifted to understand patient and graft features that affect long-term survival.
This retrospective analysis from January 1998 to December 2009 employed Kaplan-Meier analysis to evaluate survival ratios at 30 days as well as 1, 5, and 10 years. A multivariable Cox regression model considered variables of donor and recipient, gender and age, cold ischemia time (CIT), chronic renal failure etiology, time on dialysis (TD) and cause of donor death. The mismatch (MM) value was coded according to the number of antigens shared by both the donor and the recipient for HLA-A, B, and DR. The MM values ranged between 0 and 6. Two groups were analyzed according the number of shared antigens: 0 to 3 versus 4 to 6.
Among 3030 (55.85%) males and 2395 (44.15%) females, the overall mean age was 46.9 ± 13.9 years. Median follow-up was 4 years (max 13 years). Patient survival rate (SR) was 97.5% at 30 days, 87.5% at 1 year, 74.5% at 5 years, and 59.2% at 10 years. Using Cox analysis, patient SR was affected by: diabetic nephropathy (DN) hazard ratio (HR) 1.55 (95% confidence interval [CI 95%] 1.21-1.97) P = .0005; head trauma (HT) cause of donor death HR 0.83 (0.73-0.95) P = .0005 and donor age (DA) compared by 18 to 44 years: 45 to 59 years HR 1.44 (CI95% 1.00-1.30) P = .043, >60 years HR 1.41 (CI95% 1.17-1.70) P = .0004. In addition relevant factors were recipient age (RA) compared by 18 to 44 years: 45 to 59 HR 1.99 (CI95% 1.74-2.27) P < .0001, >60 years HR 3.24 (CI95% 2.79-3.75) P < .0001 and DT >7 years HR 1.33 (CI95% 1.19-1.48) P = .0001. MM HLA 0 to 3 level HR 0.78 (CI95% 0.69-0.88) P < .0001. Graft SR was 95% at 30 days, 81.6% at 1 year, 64.7% at 5 years, and 47.3% at 10 years. The relevant factors were: DN HR 1.26 (CI95% 1.01-1.57) P = .04; HT HR 0.82 (0.74-0.91) P = .0004; DA compared by 18 to 44 years: 45-59 years HR 1.19 (CI95% 1.07-1.32) P = .002, >60 years HR 1.53 (CI95% 1.30-1.80) P < .0001; RA compared by 18 to 44 years: 45-59 HR 1.33 (CI95% 1.19-1.47) P < .0001, >60 years HR 1.84 (CI95% 1.63-2.09) P < .0001; DT > 7 years HR 1.22 (CI95% 1.11-1.35) P = .0001; CIT >24 hours HR 1.13 (CI95% 1.03-1.23) P = .009 and MM HLA 0 to 3 HR 0.82 (CI95% 0.74-0.91) P = .0002.
HT as the cause of donor death and MM between 0 and 3 were associated with better patient and graft SR, DN, TD over 7 years, DA and RA over 45 were associated with lower patient SR. CIT > 24 hours, DN, TD over 7 years, as well as donor and recipient ages over 45 yr were associated with a lower graft SR.
随着短期肾移植和患者生存率的提高,重点已转向了解影响长期生存的患者和移植物特征。
这项对1998年1月至2009年12月的回顾性分析采用Kaplan-Meier分析来评估30天以及1年、5年和10年的生存率。多变量Cox回归模型考虑了供体和受体的变量、性别和年龄、冷缺血时间(CIT)、慢性肾衰竭病因、透析时间(TD)和供体死亡原因。错配(MM)值根据供体和受体在HLA-A、B和DR上共享的抗原数量进行编码。MM值范围为0至6。根据共享抗原数量分析两组:0至3与4至6。
在3030名(55.85%)男性和2395名(44.15%)女性中,总体平均年龄为46.9±13.9岁。中位随访时间为4年(最长13年)。患者生存率(SR)在30天时为97.5%,1年时为87.5%,5年时为74.5%,10年时为59.2%。使用Cox分析,患者SR受以下因素影响:糖尿病肾病(DN)风险比(HR)1.55(95%置信区间[CI 95%]1.21 - 1.97)P = 0.0005;供体死亡原因头部创伤(HT)HR 0.83(0.73 - 0.95)P = 0.0005,以及将供体年龄(DA)按18至44岁比较:45至59岁HR 1.44(CI95% 1.00 - 1.30)P = 0.043,>60岁HR 1.41(CI95% 1.17 - 1.70)P = 0.0004。此外,相关因素包括将受体年龄(RA)按18至44岁比较:45至59岁HR 1.99(CI95% 1.74 - 2.27)P < 0.0001,>60岁HR 3.24(CI95% 2.79 - 3.75)P < 0.0001,以及透析时间>7年HR 1.33(CI95% 1.19 - 1.48)P = 0.0001。MM HLA 0至3水平HR 0.78(CI95% 0.69 - 0.88)P < 0.0001。移植物SR在30天时为95%,1年时为81.6%,5年时为64.7%,10年时为47.3%。相关因素为:DN HR 1.26(CI95% 1.01 - 1.57)P = 0.04;HT HR 0.82(0.74 - 0.91)P = 0.0004;将DA按18至44岁比较:45 - 59岁HR 1.19(CI95% 1.07 - 1.32)P = 0.002,>60岁HR 1.53(CI95% 1.30 - 1.80)P < 0.0001;将RA按18至44岁比较:45 - 59岁HR 1.